LEIDEN, Netherlands & CAMBRIDGE, Mass., June 08, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced a virtual presentation of data fro
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 23, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for
… the Association for Research in Vision and Ophthalmology (ARVO) 2022 LEIDEN, Netherlands & CAMBRIDGE, Mass., April 26, … the Association for Research in Vision and Ophthalmology (ARVO) being held May 1-4, 2022, both in Denver, CO, U.S. …
ProQR has announced the completion of an in-depth strategic review designed to deliver on our commitment to advance RNA therapies for diseases with high unmet need. We are also sharing additional analyses of the sepofarsen Illuminate trial.
… Retinal Cell and Gene Therapy Innovation Summit and the ARVO 2022 Annual Meeting Corporate strategy to focus on … the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, May 1-4, 2022. Operational u pdates The …
